港股異動丨心瑋醫療-B大漲14%創逾2年新高 年內累漲超88% 較去年8月低點反彈超2.4倍!
心瑋醫療-B(6609.HK)今日逆勢走強,盤中一度大漲14.36%至41.4港元,股價創2023年5月以來逾2年新高,年內累漲超88%。該股去年8月26日盤中曾觸及歷史低位12.1港元,後股價觸底反彈,近乎連月穩步增長,迄今逾10個月時間已反彈超2.4倍。消息面上,創新藥、醫療器械板塊迎來多項重磅支持政策出臺。其中,國家醫保局、國家衛生健康委近日聯合印發《支持創新藥高質量發展的若幹措施》助力創新藥發展。國家藥監局最新亦發佈十項舉措支持高端醫療器械創新發展。機構普遍認爲,全產業鏈支持創新藥、醫療器械發展政策持續落地,對相關板塊長期利好。2025年國內創新藥產業有望迎來拐點,產業運行趨勢由資本驅動轉向盈利驅動,板塊有望迎來業績與估值雙重修復投資機會。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.